Provider Research

APA’s 2017 Consensus on Ketamine: A Paradigm Shift in Treating Mood Disorders

web-admin / November 22, 2024

Introduction:The 2017 consensus statement by the APA Council of Research Task Force on Novel Biomarkers and Treatments, led by Sanacora […]

Provider Research

Cannabis, Lung Cancer, and Pulmonary Health: Insights from Jett et al. (2018)

web-admin / November 22, 2024

Introduction:The increasing prevalence of cannabis use necessitates an understanding of its potential pulmonary risks, including its association with lung cancer.

Provider Research

Key Considerations for Psychedelic Therapy Roll-Out: Xenakis & Shannon (2024)

web-admin / November 22, 2024

Introduction:The adoption of psychedelic-assisted therapy (PAT) into mainstream psychiatry poses unique challenges. In their 2024 review, published in Current Opinion

Provider Research

Drug-Drug Interactions Between Purified CBD and ASM: Final Analysis (Gaston et al., 2023)

web-admin / November 22, 2024

Introduction:In a 2023 study published in Epilepsia Open, Gaston et al. provided a comprehensive analysis of potential drug-drug interactions (DDIs)

VitalPoint Technologies, Inc.

Disclaimer

None of the statements in this announcement or via any web sites linked herein have been evaluated by the FDA. Furthermore, none of the statements in this announcement or any web sites linked herein should be construed as dispensing medical advice or making claims regarding the cure of diseases. You should consult a licensed health care professional before starting any supplement, dietary, or exercise program, especially if you are pregnant or have any pre-existing injuries or medical conditions. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.